Drug Approval | March 07, 2022
NATCO launches first generic version of Revlimid in the US
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
According to an Injury Surveillance Report by NCA last year, 14.75 % of players sustained shoulder injuries, 13.11% of players sustained knee injuries and almost 74 % players suffer from career-threatening Anterior Cruciate Ligament (ACL) injuries in the 1st two years of return to sport
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
WuXi STA’s drug product site in Wuxi City offers a full range of services including formulation development and manufacturing for a broad range of oral and injectable dosage forms
Launched in 2020, C-TAP aims to facilitate timely, equitable and affordable access to Covid-19 health products by boosting their production and supply through open, non-exclusive licensing agreements
It plans launch various other health monitoring tools for smartphones, making existing devices obsolete
Ten new Ayush hospitals and one Ayurvedic college will be set up in Nagaland and Mizoram
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
This ninth update of WHO’s guideline on therapeutics includes a recommendation that casirivimab-imdevimab not be used for patients infected with the Omicron variant
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
Subscribe To Our Newsletter & Stay Updated
